Continuation of The Collaborative Islet Transplantation Registry (CITR)

协作胰岛移植登记处 (CITR) 的延续

基本信息

批准号：
10513103
负责人：
Elizabeth Holly Payne
金额：
$ 73.46万
依托单位：
THE EMMES COMPANY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-15 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10513103
关键词：
Address Allogenic Autologous Biometry Case Report Form Cell physiology Clinical Clinical Treatment Collection Communication Communities Complex Data Data Collection Data Reporting Development Diabetes Mellitus Ensure Funding Goals Health Human Hypoglycemia Insulin-Dependent Diabetes Mellitus International Islet Cell Islets of Langerhans Islets of Langerhans Transplantation Journals Knowledge Lead Leadership Manuscripts Methods National Institute of Diabetes and Digestive and Kidney Diseases Outcome Pancreatectomy Peer Review Persons Positioning Attribute Publications Refractory Registries Research Personnel Resolution Running Safety Secure Security Site Source Statistical Data Interpretation Therapeutic Transplantation U-Series Cooperative Agreements Validation Work base beta cell replacement cell replacement therapy data exchange data registry experience flexibility follow-up meetings multidisciplinary new technology posters programs quality assurance response success transplant registry

项目摘要

PROJECT SUMMARY This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021 as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee, and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.

项目概要此应用程序响应 RFA-DK-21-013，描述了全面的数据和统计协调 2022-2027 年协作胰岛移植登记中心 (DSCC)。 2017-2021 年持续作为 CITR-DSCC，Emmes 继续与 NIDDK 项目办公室、监督委员会、 CITR 调查员支持已建立的 CITR 注册中心。该注册表包括同种异体和自体胰岛移植，以及任何其他应该进行的β细胞替代疗法其次是解决以严重低血糖为特征的难治性血糖不稳定的有效性和安全性 1 型糖尿病患者或因任何原因（包括治疗原因）缺乏胰岛的患者的发作胰腺切除术或任何胰岛细胞功能丧失。有关更多详细信息，请参阅“具体目标”部分。